English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

SRSF2 and U2AF1 mutations in primary myelofibrosis are associated with JAK2 and MPL but not calreticulin mutation and may independently reoccur after allogeneic stem cell transplantation Leukemia (2015) 29, 253–255; doi:10.1038/leu.2014.277 Spliceosome gene mutations are among the 50–60 driver mutations underlying myelodysplastic syndromes (MDSs).1 U2AF1 mutations for example have been reported to occur in up to 16 % of primary myelofibrosis (PMF), and was found to be associated with anemia and thrombocytopenia in PMF.2 We could show that spliceosome gene mutations are already present in early stages of PMF before fibrosis and cytopenia become manifest.3 Recently, a negative association between mutations of calreticulin (CALR) and spliceosome genes has been described.4 CALR is a Ca2+-binding protein, which was found in 2013 t

leukemia

SRSF2 and U2AF1 mutations in primary myelofibrosis are associated with JAK2 and MPL but not calreticulin mutation and may independently reoccur after allogeneic stem cell transplantation